← Back to Screener
PUMA BIOTECHNOLOGY INC (PBYI)
Price$7.37
Favorite Metrics
Price vs S&P 500 (26W)37.15%
Price vs S&P 500 (4W)12.57%
Market Capitalization$374.96M
P/E Ratio (Annual)12.05x
All Metrics
P/CF (Annual)8.97x
Book Value / Share (Quarterly)$2.59
P/TBV (Annual)3.37x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)0.05%
Cash Flow / Share (Quarterly)$0.83
Price vs S&P 500 (YTD)21.41%
Gross Margin (TTM)74.53%
Net Profit Margin (TTM)13.62%
EPS (TTM)$0.61
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$0.61
Revenue Growth (5Y)0.29%
EPS (Annual)$0.61
ROI (Annual)20.35%
Gross Margin (Annual)74.53%
Net Profit Margin (5Y Avg)4.89%
Cash / Share (Quarterly)$1.93
P/E Basic Excl Extra (TTM)12.05x
Revenue Growth QoQ (YoY)27.72%
P/E Normalized (Annual)12.05x
ROA (Last FY)14.38%
Revenue Growth TTM (YoY)-0.91%
EBITD / Share (TTM)$0.97
ROE (5Y Avg)-66.97%
Operating Margin (TTM)16.33%
Cash Flow / Share (Annual)$0.83
P/B Ratio2.88x
P/B Ratio (Quarterly)2.30x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.61x
Net Interest Coverage (TTM)15.07x
ROA (TTM)15.36%
EPS Growth QoQ (YoY)-33.47%
EV / EBITDA (TTM)7.47x
EPS Incl Extra (Annual)$0.61
Current Ratio (Annual)2.00x
Quick Ratio (Quarterly)1.89x
3-Month Avg Trading Volume0.39M
52-Week Price Return159.38%
EV / Free Cash Flow (Annual)8.81x
P/E Incl Extra (TTM)12.05x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.76
P/S Ratio (Annual)1.64x
Asset Turnover (Annual)1.06x
52-Week High$7.90
Operating Margin (5Y Avg)8.42%
EPS Excl Extra (Annual)$0.61
CapEx CAGR (5Y)-67.65%
26-Week Price Return45.90%
Quick Ratio (Annual)1.89x
13-Week Price Return16.36%
Total Debt / Equity (Annual)0.17x
Current Ratio (Quarterly)2.00x
Enterprise Value$367.848
Revenue / Share Growth (5Y)-4.53%
Asset Turnover (TTM)1.13x
Book Value / Share Growth (5Y)23.62%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)8.17x
Pretax Margin (Annual)15.67%
Cash / Share (Annual)$1.93
3-Month Return Std Dev71.08%
Gross Margin (5Y Avg)74.13%
Net Income / Employee (TTM)$0
ROE (Last FY)23.87%
Net Interest Coverage (Annual)15.07x
EPS Basic Excl Extra (Annual)$0.61
P/FCF (TTM)8.99x
Receivables Turnover (TTM)5.33x
EV / Free Cash Flow (TTM)8.81x
Total Debt / Equity (Quarterly)0.17x
EPS Incl Extra (TTM)$0.61
Receivables Turnover (Annual)5.33x
ROI (TTM)20.59%
P/S Ratio (TTM)1.64x
Pretax Margin (5Y Avg)4.92%
Revenue / Share (Annual)$4.51
Tangible BV / Share (Annual)$1.76
Forward P/E29.48x
Free OCF CAGR (5Y)11.98%
Price vs S&P 500 (52W)124.28%
P/E Ratio (TTM)12.05x
EPS Growth TTM (YoY)-0.07%
Year-to-Date Return25.55%
5-Day Price Return-1.32%
EPS Normalized (Annual)$0.61
ROA (5Y Avg)5.02%
Net Profit Margin (Annual)13.62%
Month-to-Date Return16.90%
Cash Flow / Share (TTM)$0.31
EBITD / Share (Annual)$0.97
Operating Margin (Annual)16.33%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)8.97x
ROI (5Y Avg)-2.75%
P/E Excl Extra (TTM)12.05x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.61
P/TBV (Quarterly)3.37x
P/B Ratio (Annual)2.30x
Inventory Turnover (TTM)8.17x
Pretax Margin (TTM)15.67%
Book Value / Share (Annual)$2.59
Price vs S&P 500 (13W)13.49%
Beta1.26x
P/FCF (Annual)8.99x
Revenue / Share (TTM)$4.42
ROE (TTM)27.81%
52-Week Low$2.75
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.14
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PBYIPUMA BIOTECHNOLOGY INC | 1.64x | -0.91% | 74.53% | — | $7.37 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Puma Biotechnology is an oncology-focused biopharmaceutical company that commercializes NERLYNX, an oral medication for HER2-positive breast cancer, and is developing alisertib, an aurora kinase A inhibitor. The company targets improvements in cancer treatment outcomes through its portfolio of targeted therapies.